ERBB2 and breast carcinoma: The aptamer–Dox complex, which was formulated by intercalating Dox molecules into the aptamers, could selectively deliver Dox to HER2-positive breast cancer cells and retained the cytotoxicity of Dox against these cells; the aptamers preferentially target to HER2-positive breast cancer cells but not to HER2-negative cells [108].